• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Goldman Sachs raises Intuitive Surgical price target | Wall Street Beat

Goldman Sachs raises Intuitive Surgical price target | Wall Street Beat

October 21, 2011 By MassDevice staff

MassDevice.com Wall Street Beat

Goldman Sachs analysts raised their price target for shares of Intuitive Surgical (NSDQ:ISRG) after a strong third-quarter showing from the robotic surgery firm.

The researchers boosted their target from $362 to $412 and maintained their “neutral” rating in a note to investors.

“The quarter’s results continue to demonstrate solid underlying demand for da Vinci surgical robots even in the face of what appears to be a tough capex environment and channel checks suggesting high-end equipment remains a low priority for hospitals,” according to Goldman Sachs. “Unless a source of material weakness is displayed by Intuitive Surgical’s business, current momentum in the stock is unlikely to reverse.”

Sign up to get our free newsletters delivered straight to your inbox

Here’s how the investment bank now estimates ISRG’s annual earnings per share for the next four years:

$11.94

YEAR FORMER CURRENT % CHANGE
2011 $11.43 4.5%
2012

$13.89 $14.43 3.9%
2013

$16.34 $17.05 3.8%
2014

$18.71 $19.65 5.0%

Intuitive’s sales and earnings surged for the third quarter, sending share prices up 11.2 percent to a 52-week high of $425.49 Oct. 19, before settling to close at $417.62. ISRG shares were trading at $414.78 today as of about 1:15, down 0.87 percent on the day.

Edwards< Mela top list of med-tech performers

Edwards Lifesciences and Mela Sciences topped the list of the best five stock performers in med-tech yesterday, as ranked by Financial News Network:

  1. Edwards Lifesciences (NYSE:EW): 2.86%
  2. Mela Sciences (NSDQ:MELA): 2.86%
  3. Idexx Laboratories (NSDQ:IDXX): 2.53%
  4. Mindray Medical (NYSE:MR): 2.0%
  5. Sirona Dental Systems (NSDQ:SIRO): 1.08%

Read more

Is BSX a good bet or not?

Two Wall Street watchers have differing views on Boston Scientific stock, with one recommending it as a good long-term buy and the other panning its chances of a successful turnaround.

Writing on SeekingAlpha.com, Stephen Simpson and self-styled blogger “Vatalyst” lay out their conclusions:

“With a new caretaker CEO at the reins, but only for a year, it an open question as to whether investors can reasonably expect any near-term progress. While there are some bright spots deep in the pipeline, it is going to take many years for them to bear fruit, and BSX will find itself having to battle for share amidst established competition,” according to Simpson. “All in all, this is an investment that requires a great deal of faith – and hope and faith are seldom great partners to have in an investment.”

“Boston Scientific’s share price has, in my view, been penalized too heavily by the market. News such as its full enrollment in clinical trials to evaluate its WallFlex Biliary RX covered stent – in a market segment from which Abbott Laboratories (NYSE:ABT) announced its withdrawal in June due to decreasing market share – shows that the company is preparing for growth in its specialized areas,” Vitalyst countered. “With the share price at the low end of its 52-week trading range of $5.41 to $7.96, a forward price-to-earnings ratio of less than 11, and a reported book value of $7.55, BSX is a stock that I believe offers excellent value in a poorly performing sector. It’s a buy.”

Boston Scientific beat The Street with its Q3 earnings, reporting profits of $142 million, or 9 cents per diluted share, on sales of $1.87 billion for the three months ended Sept. 30. That compares with profits of $190 million, or 12 cents diluted EPS, on sales of $1.92 billion during the same period last year.

Filed Under: News Well, Wall Street Beat Tagged With: Boston Scientific, Edwards Lifesciences, Intuitive Surgical, MELA Sciences Inc.

More recent news

  • Alpheus Medical raises $52M for ultrasound-activated tumor therapy
  • Elucent Medical wins FDA breakthrough nod for in-body spatial intelligence system
  • EndoQuest Robotics completes first cases in pivotal surgical robot trial
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Intuitive Surgical is making a CEO change

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy